CD98 Expression Is Associated with Poor Prognosis in Resected Non-Small-Cell Lung Cancer with Lymph Node Metastases
- Kyoichi Kaira MD, PhD,
- Noboru Oriuchi MD, PhD,
- Hisao Imai MD,
- Kimihiro Shimizu MD, PhD,
- Noriko Yanagitani MD, PhD,
- Noriaki Sunaga MD, PhD,
- Takeshi Hisada MD, PhD,
- Osamu Kawashima MD, PhD,
- Yosuke Kamide MD,
- Tamotsu Ishizuka MD, PhD,
- Yoshikatsu Kanai MD, PhD,
- Takashi Nakajima MD, PhD,
- Masatomo Mori MD, PhD
- … show all 13 hide
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The purpose of this study was to evaluate the prognostic value of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in resectable non-small-cell lung cancer (NSCLC) patients with N1 and N2 nodal involvement.
A total of 220 consecutive patients were retrospectively reviewed. Immunohistochemical expression of LAT1, CD98, Ki-67 labeling index, vascular endothelial growth factor (VEGF), and microvessel density (MVD) was correlated with clinical features and prognosis of patients after complete resection of the tumor.
Positive expression of LAT1 and CD98 was recognized in 60% (132/220) and 47% (103/220), respectively (P = 0.021). A positive rate of LAT1 expression was significantly higher in squamous cell carcinoma (SQC) (91%; 65/71) and large cell carcinoma (LCC) (82%; 9/11) than in adenocarcinoma (AC) (42%; 58/138). Moreover, a positive rate of CD98 expression was also significantly higher in SQC (76%; 54/71) and LCC (73%; 8/11) than in AC (30%; 42/138). LAT1 expression was significantly correlated with CD98, Ki-67 labeling index, VEGF, and MVD. The 5-year survival rates of LAT1-positive and LAT1-negative patients and CD98-positive and CD98-negative patients, were 43% and 48% (P = 0.1043), respectively and 39% and 50% (P = 0.0239), respectively. Multivariate analysis confirmed that positive expression of CD98 was an independent factor for predicting a poor prognosis.
In our limited series, CD98 is a pathological factor that predicts prognosis in resectable adenocarcinoma patients with N2 disease.
- Shottenfeld D. Epidemiology of lung cancer. Philadelphia, PA: Lippincott-Raven; 1996.
- Graziano SL. Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer. 1997;17(Suppl. 1):S37–58. CrossRef
- Mountain CF. Revision in the International System for Staging Lung Cancer. Chest. 1997;11:1710–7. CrossRef
- Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol. 2000;18:2981–9.
- Leong SS, Rocha Lima CM, Sherman CA, et al. The 1997 International Staging System for non-small cell lung cancer: have all the issues been addressed? Chest. 1999;115:242–8. CrossRef
- Jassem J, Skokowski J, Dziadziuszko R, et al. Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. J Thorac Cardiovasc Surg. 2000;119:1141–6. CrossRef
- Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer: adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol. 1997;15:2996–3018.
- Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev. 1990;70:43–77.
- McGivan JD, Pastor-Anglada M. Regulatory and molecular aspects of mammalian amino acid transport. Biochem J. 1994;299:321–34.
- Oxender DL, Christensen HN. Evidence for two types of mediation of neutral amino acid transport in Ehrlich cells. Nature. 1963;197:765–7. CrossRef
- Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 1998;273:23629–32. CrossRef
- Yanagida O, Kanai Y, Chairoungdua A, et al. Human L-type amino acid transporter 1 (LAT 1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 2001;1514:291–302. CrossRef
- Ohkame H, Masuda H, Ishii Y, Kanai Y. Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models. J Surg Oncol. 2001;78:265–71; discussion 271–2. CrossRef
- Kaira K, Oriuchi N, Imai H, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer. 2008;98:742–8. CrossRef
- Kaira K, Oriuchi N, Imai H, et al. Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. Pathol Res Pract. 2008;204:553–61. CrossRef
- Kaira K, Oriuchi N, Imai H, et al. L-type amino acid transporter 1 (LAT1) and CD98 expression in the primary site and the metastatic site of human neoplasms. Cancer Sci. 2008;99:3280–6. CrossRef
- Nawashiro H, Otani N, Shinomiya N, et al. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer. 2006;119:484–92. CrossRef
- Chairoungdua A, Segawa H, Kim JY, et al. Identification of an amino acid transporter associated with the cystinuria-related type II membrane glycoprotein. J Biol Chem. 1999;274:28845–8. CrossRef
- Matsuo H, Tsukada S, Nakata T, et al. Expression of a system L neutral amino acid transporter at the blood–brain barrier. Neuroreport. 2000;11:3507–11. CrossRef
- Buck AC, Schirmeister HH, Guhlmann CA, et al. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J Nucl Med. 2001;42:721–5.
- Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1–8.
- Mineo TC, Ambrogi V, Baldi A, et al. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumor vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol. 2004;57:591–7. CrossRef
- Kaira K, Oriuchi N, Imai H, et al. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer. 2009;66:120–6.
- Kaira K, Oriuchi N, Imai H, et al. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. Cancer Sci. 2009;100:249–54. CrossRef
- Imai H, Kaira K, Oriuchi N, et al. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer. Histopathology. 2009;54:804–13.
- Rintoul RC, Buttery RC, Mackinnon AC, et al. Cross-linking CD98 promotes integrin-like signaling and anchorage-independent growth. Mol Biol Cell. 2002;13:2841–52. CrossRef
- Takeuchi H, Kubota T, Kitai R, et al. CD98 immunoreactivity in multinucleated giant cells of glioblastomas: an immunohistochemical double labeling study. Neuropathology. 2008;28:127–31. CrossRef
- Nakanishi K, Ogata S, Matsuo H, et al. Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch. 2007;451:681–90. CrossRef
- Fucks BC, Finger RE, Onan MC, Bode BP. ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells. Am J Physiol Cell Physiol. 2007;293:55–63. CrossRef
- Winton T, Livingston R, Johnson D, et al. A prospective randomized trial of adjuvant vinorelbine (VNR) and cisplatin (CIS) in completely resected stage Ib and II non-small cell lung cancer (NSCLC). Intergroup JBR 10. N Engl J Med. 2005;352:2589–97. CrossRef
- Arriagada R, Bergman B, Dunant A, et al. Cisplatin based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med. 2004;350:351–60. CrossRef
- Douillard J, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association[ANITA]):a randomized control trial. Lancet Oncol. 2006;7:719–27. CrossRef
- Kang CH, Ra YJ, Kim YT, et al. The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 nonsmall-cell lung cancer. Ann Thorac Surg. 2008;86:109–7. CrossRef
- Sayar A, Turna A, Kilicgun A, et al. Prognostic significance of surgical-pathologic multiple-station N1 disease in non-small cell carcinoma of the lung. Eur J Cardiothoracic Surg. 2004;25:434–8. CrossRef
- Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26:3552–9. CrossRef
- CD98 Expression Is Associated with Poor Prognosis in Resected Non-Small-Cell Lung Cancer with Lymph Node Metastases
Annals of Surgical Oncology
Volume 16, Issue 12 , pp 3473-3481
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors
- Kyoichi Kaira MD, PhD (1)
- Noboru Oriuchi MD, PhD (2)
- Hisao Imai MD (1)
- Kimihiro Shimizu MD, PhD (3)
- Noriko Yanagitani MD, PhD (1)
- Noriaki Sunaga MD, PhD (1)
- Takeshi Hisada MD, PhD (1)
- Osamu Kawashima MD, PhD (4)
- Yosuke Kamide MD (5)
- Tamotsu Ishizuka MD, PhD (1)
- Yoshikatsu Kanai MD, PhD (6)
- Takashi Nakajima MD, PhD (7)
- Masatomo Mori MD, PhD (1)
- Author Affiliations
- 1. Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
- 2. Department of Diagnostic Radiology and Nuclear medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
- 3. Department of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan
- 4. Department of Surgery, National Nishi-Gunma Hospital, Shibukawa, Gunma, Japan
- 5. Department of Respiratory Medicine, National Nishi-Gunma Hospital, Shibukawa, Gunma, Japan
- 6. Division of Bio-system Pharmacology, Department of Pharmacology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
- 7. Department of Tumor Pathology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan